Biotechnology & Life Sciences Global On demand · 24-48h

Global Biomarkers Discovery Market Strategic Research Report

Global Biomarkers Discovery Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Biomarkers Discovery Market
$68.4B2025
9.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Genomic & Genetic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers

By Application: Oncology Applications, CNS & Neurological Applications, Drug Development & Clinical Trials

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$68.4B
Billion USD
Forecast CAGR
9.6%
2025-2032
Forecast 2032
$129.9B
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

The global biomarkers discovery market represents one of the most consequential segments within life sciences, sitting at the intersection of precision medicine, drug development, and molecular diagnostics. Valued at approximately USD 68.4 billion in 2024, the market encompasses the identification, validation, and commercialization of biological indicators—ranging from genomic and proteomic signatures to imaging and metabolomic markers—used across clinical research, therapeutic development, and disease monitoring. Its strategic importance has grown substantially as pharmaceutical companies, academic medical centers, and diagnostic developers converge on biomarker data as the foundational currency of personalized treatment protocols and regulatory submissions. The breadth of applications, spanning oncology, cardiovascular disease, neurological disorders, and infectious disease, ensures that demand for biomarker discovery capabilities remains structurally expansive rather than cyclically constrained.

Market snapshot

Global Biomarkers Discovery Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$68.4B
2025
Forecast
$129.9B
2032
CAGR
9.6%
2025–2032
Области
5
global
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Genomic & Genetic BiomarkersProteomic BiomarkersMetabolomic Biomarkers
By Application
Oncology ApplicationsCNS & Neurological ApplicationsDrug Development & Clinical Trials

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value Forecast, 2025-2032 (Value)
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
  • 3.1 Market by Type Overview
  • 3.2 Genomic & Genetic Biomarkers (Value)
  • 3.3 Proteomic Biomarkers (Value)
  • 3.4 Metabolomic Biomarkers (Value)
  • 3.5 Imaging Biomarkers (Value)
  • 3.6 Epigenetic Biomarkers (Value)
04Market Segmentation by Application
  • 4.1 Market by Application Overview
  • 4.2 Oncology & Cancer Biomarker Discovery (Value)
  • 4.3 Cardiovascular Disease Biomarker Discovery (Value)
  • 4.4 Neurological & CNS Disorder Biomarker Discovery (Value)
  • 4.5 Infectious Disease & Immunology Biomarker Discovery (Value)
  • 4.6 Drug Development & Clinical Trial Stratification (Value)
05Regional Market Forecast
  • 5.1 Regional Revenue Share & CAGR (2024 vs 2032)
  • 5.2 Asia Pacific (Value)
  • 5.3 North America (Value)
  • 5.4 Europe (Value)
  • 5.5 Middle East & Africa
  • 5.6 Latin America
06Country-Level Market Forecast
  • 6.1 Top Countries Overview
  • 6.2 United States
  • 6.3 Germany
  • 6.4 United Kingdom
  • 6.5 China
  • 6.6 Japan
  • 6.7 Canada
07Growth Drivers & Inhibitors
  • 7.1 Expansion of Multi-Omics Platforms Accelerating Biomarker Identification Throughput
  • 7.2 Rising Companion Diagnostic Mandates in FDA and EMA Oncology Drug Approvals
  • 7.3 Increased NIH, EU Horizon, and Private Equity Funding Directed at Precision Medicine Infrastructure
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific — Revenue, Strategy, Key Products
  • 8.2 Bio-Rad Laboratories — Revenue, Strategy, Key Products
  • 8.3 Illumina Inc. — Revenue, Strategy, Key Products
  • 8.4 Merck KGaA (MilliporeSigma) — Revenue, Strategy, Key Products
  • 8.5 Agilent Technologies — Revenue, Strategy, Key Products
  • 8.6 QIAGEN N.V. — Revenue, Strategy, Key Products
  • 8.7 F. Hoffmann-La Roche Ltd. — Revenue, Strategy, Key Products
  • 8.8 Becton, Dickinson and Company — Revenue, Strategy, Key Products
  • 8.9 Myriad Genetics Inc. — Revenue, Strategy, Key Products
  • 8.10 Bruker Corporation — Revenue, Strategy, Key Products
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity
  • 9.2 Market Share Analysis (2024)
  • 9.3 Competitive Positioning Matrix
  • 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors
  • 11.2 Economic Factors
  • 11.3 Social & Demographic Factors
  • 11.4 Technological Factors
  • 11.5 Legal & Regulatory Factors
  • 11.6 Environmental Factors
12SWOT Analysis
  • 12.1 Market-Level Strengths
  • 12.2 Market-Level Weaknesses
  • 12.3 Strategic Opportunities
  • 12.4 External Threats
13Future Trends & Outlook
  • 13.1 AI-Driven Biomarker Pattern Recognition in Large-Scale Genomic Cohort Datasets
  • 13.2 Liquid Biopsy Biomarker Panels Displacing Tissue-Based Discovery Workflows
  • 13.3 Single-Cell Sequencing Enabling Spatially Resolved Biomarker Discovery in Tumor Microenvironments
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the biomarkers discovery market?
The global biomarkers discovery market was valued at approximately USD 68.4 billion in 2024 and is projected to reach USD 142.7 billion by 2032, reflecting the accelerating integration of biomarker science into drug development and precision diagnostics pipelines.
What is the CAGR of the biomarkers discovery market?
The global biomarkers discovery market is forecast to grow at a compound annual growth rate of approximately 9.6% over the period from 2025 to 2032, driven by expanding multi-omics adoption and rising companion diagnostic requirements in regulatory submissions.
What is driving growth in the biomarkers discovery market?
Three principal forces are propelling expansion. First, the maturation and cost reduction of multi-omics platforms—including next-generation sequencing and mass spectrometry proteomics—has dramatically increased the rate at which novel biomarkers can be identified and cross-validated. Second, regulatory agencies including the FDA and EMA have increasingly required companion diagnostic evidence in oncology drug approvals, creating a near-mandatory commercial demand for biomarker discovery services. Third, coordinated public and private funding—including NIH's All of Us program, EU Horizon Europe grants, and a surge in venture capital directed at liquid biopsy and early cancer detection—has materially expanded the resource base available for early-stage biomarker research.
Who are the leading companies in the biomarkers discovery market?
Key participants include Thermo Fisher Scientific, which supplies a broad portfolio of mass spectrometry, proteomics, and genomic instruments central to biomarker workflows; Illumina Inc., whose sequencing platforms underpin the majority of genomic biomarker discovery globally; Roche, with integrated diagnostics and companion diagnostic development capabilities; QIAGEN, a leader in sample preparation and biomarker assay kits; and Agilent Technologies, which provides analytical instrumentation and bioinformatics tools widely used in metabolomic and proteomic biomarker discovery.
Which region dominates the biomarkers discovery market?
North America, led by the United States, commands the largest share of the global biomarkers discovery market, accounting for approximately 42% of revenue in 2024. This dominance reflects the concentration of major pharmaceutical and biotechnology companies, the volume of NIH-funded research infrastructure, and the FDA's advanced companion diagnostic regulatory framework, all of which create a dense and well-funded ecosystem for biomarker identification and validation activity.
What segments are covered in this report?
The report covers the market across biomarker type segments—including genomic and genetic biomarkers, proteomic biomarkers, metabolomic biomarkers, imaging biomarkers, and epigenetic biomarkers—and across application segments encompassing oncology, cardiovascular disease, neurological and CNS disorders, infectious disease and immunology, and drug development and clinical trial stratification. Regional coverage spans North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, with country-level detail for the United States, Germany, United Kingdom, China, Japan, and Canada.
What is the forecast period covered in this report?
This report covers a forecast period from 2025 to 2032, with 2024 as the base year. Historical trend analysis extends back to 2019 to provide a six-year contextual baseline against which forecast trajectories are calibrated.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.